Now showing items 1-5 of 5

    • Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease 

      Kirsebom, Bjørn-Eivind; Nordengen, Kaja; Selnes, Per; Waterloo, Knut; Torsetnes, Silje Bøen; Gísladóttir, Berglind; Brix, Britta; Vanmechelen, Eugeen; Bråthen, Geir; Hessen, Erik; Aarsland, Dag; Fladby, Tormod (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-10)
      <i>Introduction</i>: The cerebrospinal fluid neurogranin (Ng)/β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta-amyloid (Aβ) clearance. We hypothesize that increased Ng/BACE1 ratio predicts the earliest cognitive decline in Alzheimer’s disease.<p> <p><i>Methods</i>: We compared Ng/BACE1 levels between cases with subjective ...
    • Exploration of plasma lipids in mild cognitive impairment due to Alzheimer's disease 

      Bergland, Anne Katrine; Proitsi, Petroula; Kirsebom, Bjørn-Eivind; Sønnesyn, Hogne; Hye, Abdul; Larsen, Alf Inge; Xu, Jin; Legido-Quigley, Cristina; Rajendran, Lawrence; Fladby, Tormod; Aarsland, Dag (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-09-29)
      <p><i>Background: </i>Lipids have important structural roles in cell membranes and changes to these membrane lipids may influence β- and γ-secretase activities and thus contribute to Alzheimer’s disease (AD) pathology. <p><i>Objective:</i> To explore baseline plasma lipid profiling in participants with mild cognitive impairment (MCI) with and without AD pathology. <p><i>Methods: </i>We identified ...
    • In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion 

      Hessen, Erik; Kirsebom, Bjørn-Eivind; Eriksson, Cecilia Magdalena; Eliassen, Carl Fredrik Andestad; Nakling, Arne; Bråthen, Geir; Waterloo, Knut; Aarsland, Dag; Fladby, Tormod (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-22)
      <i>Background:</i> In the care of persons with cognitive problems, it is important to use a valid mild cognitive impairment (MCI) criterion that discriminates well between normal and pathological aging.<p> <p><i>Objective:</i> To find the brief neuropsychological screening criterion that best correlates with cerebrospinal fluid (CSF) biomarkers for cognitive decline and dementia in persons ...
    • Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia 

      Eliassen, Ingvild Vøllo; Fladby, Tormod; Kirsebom, Bjørn-Eivind; Waterloo, Knut; Eckerström, Marie; Wallin, Anders; Bråthen, Geir; Aarsland, Dag; Hessen, Erik (Journal article; Tidsskriftartikkel; Peer reviewed, 2020)
      Objective: To assess the role of brief neuropsychological assessments in prediction and identification of Alzheimer’s disease (AD) pathology and progression to AD dementia. Method: Adults (N = 255; range = 40–81 years) with self-reported cognitive decline underwent baseline and 2-year follow-up clinical assessment, including a brief neuropsychological screening and lumbar puncture. Five different ...
    • Screening for Alzheimer’s Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients 

      Kirsebom, Bjørn-Eivind; Espenes, Ragna; Waterloo, Knut; Hessen, Erik; Johnsen, Stein Harald; Bråthen, Geir; Aarsland, Dag; Fladby, Tormod (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-11-07)
      <p>Background</i>: Cognitive assessment is essential in tracking disease progression in AD. Presently, cohorts including preclinical at-risk participants are recruited by different means, which may bias cognitive and clinical features. We compared recruitment strategies to levels of cognitive functioning.<p> <p><i>Objective</i>: We investigate recruitment source biases in self-referred and ...